Találati lista | Tudóstér

001-es BibID:	BIBFORM028490
Első szerző:	Kiss Lajos Sándor
Cím:	Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease / Kiss, L. S., Szamosi, T., Molnar, T., Miheller, P., Lakatos, L., Vincze, A., Palatka, K., Barta, Z., Gasztonyi, B., Salamon, A., Horvath, G., Tóth, G. T., Farkas, K., Banai, J., Tulassay, Z., Nagy, F., Szenes, M., Veres, G., Lovasz, B. D., Vegh, Z., Golovics, P. A., Szathmari, M., Papp, M., Lakatos, P. L.
Dátum:	2011
ISSN:	0269-2813
Megjegyzések:	Adalimumab is a fully human monoclonal antibody targeting tumour necrosis factor with proven efficacy in the treatment of Crohn's disease (CD). AIM: To investigate the predictors of medium-term clinical efficacy and mucosal healing during adalimumab therapy, in patients with CD, in specialised centres approved for biological therapy in Hungary. METHODS: Data capture of the 201 CD patients was standardised and prospective (male/female: 112/89, median age: 33.0 years, duration: 8 years). Previous infliximab therapy had been administered in 48% of patients, concomitant steroids in 41%, azathioprine in 69% and combined therapy in 27% of patients. RESULTS: Overall clinical response and remission rates at 24 weeks were 78% and 52%, respectively; at 52 weeks were 69% and 44%, respectively. Endoscopic improvement and healing were achieved in 43% and 24% of patients. In a logistic regression model, clinical efficacy and CRP at week 12, need for combined immunosuppression at induction, shorter disease duration and smoking were identified as independent predictors for 12-month clinical outcome, whereas CRP at week 12, clinical remission at week 24, inflammatory parameters and nonsmoking were associated to endoscopic improvement/healing. Intensification to weekly dosing was needed in 16% of patients. Parallel azathioprine therapy and clinical remission at week 12 were inversely associated with dose escalation. CONCLUSIONS: Clinical efficacy and normalised CRP at week 12 (early deep clinical remission) are associated with medium-term clinical efficacy and mucosal healing during adalimumab therapy, whereas need for combined immunosuppression at induction and smoking status are predictors for non-response. Parallel azathioprine therapy may decrease the probability for dose escalation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Alimentary Pharmacology & Therapeutics. - 34 : 8 (2011), p. 911-922. -
További szerzők:	Szamosi Tamás Molnár Tamás (orvos Szeged) Miheller Pál Lakatos László (Veszprém) Vincze A. (orvos Pécs) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Barta Zsolt (1964-) (belgyógyász, gasztroenterológus) Gasztonyi Beáta Salamon A. (orvos Zalaegerszeg) Horváth Gábor (orvos Miskolc) Tóth Gábor Tamás Farkas Katalin Banai János Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Nagy Ferenc (orvos Szeged) Szenes Mária Veres Gábor (1969-2020) (csecsemő- és gyermekgyógyász, gasztroenterológus) Lovász Barbara Dorottya Végh Zsuzsanna Golovics Petra Anna Szathmári Miklós Papp Mária (1975-) (belgyógyász, gasztroenterológus) Lakatos Péter (Semmelweis Egyetem)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM040343
Első szerző:	Molnár T. (orvos)
Cím:	Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy / Molnár T., Lakatos P. L., Farkas K., Nagy F., Szepes Z., Miheller P., Horváth G., Papp M., Palatka K., Nyári T., Bálint A., Lőrinczy K., Wittmann T.
Dátum:	2013
Megjegyzések:	BACKGROUND: Some of the most important questions relating to the use of biological therapy in inflammatory bowel diseases concern the duration of maintenance therapy. AIM: To assess the disease course and frequency of relapse of Crohn's disease (CD) following discontinuation of biological therapy, and to determine predictive factors for relapse. METHODS: One hundred twenty-one CD patients who had achieved clinical remission following 1 year of biological therapy and for whom biological therapy was then discontinued participated in this prospective observational study. Eighty-seven CD patients had received infliximab and 34 adalimumab. The definition of relapse was an increase of >100 points in CDAI to at least a CDAI of 150 points. RESULTS: Biological therapy was restarted within 1 year of treatment cessation in 45% of patients. Logistic regression analysis revealed that previous biological therapy (P = 0.011) and dose intensification during the 1-year course of biological therapy (P = 0.024) were associated with the need for and the time to the restarting of biological therapy. Smoking was observed to have an effect that was not statistically significant (P = 0.053). CONCLUSIONS: Biological therapy was restarted a median of 6 months after discontinuation in almost half of Crohn's disease patients in who had been in clinical remission following 1 year of biological therapy. These results suggest that, in the event of the presence of certain predictive factors, biological therapy should probably be continued for more than 1 year by most patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Alimentary Pharmacology and Therapeutics. - 37 : 2 (2013), p. 225-233. -
További szerzők:	Lakatos Péter (Semmelweis Egyetem) Farkas K. Nagy Ferenc (orvos Szeged) Szepes Zoltán Miheller Pál Horváth G. Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Nyári Tibor Bálint Anita Lőrinczy K. Wittmann Tibor
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM089326
035-os BibID:	(WoS)000602715700022 (Scopus)85098011271
Első szerző:	Tornai Dávid (hepatológia, biomarker kutatás)
Cím:	Editorial : serologic antibodies in primary sclerosing cholangitis - a tell-tale sign of compromised gut-liver immunity? / Tornai Dávid, Papp Mária
Dátum:	2021
ISSN:	0269-2813 1365-2036
Megjegyzések:	Biomarkers provide tools for clinicians to help decision making and in some cases contribute to better understanding of disease pathology. The recent publication from Wunsch et al.1 is an example. It meets a long-standing need for prognostic tools in primary sclerosing cholangitis (PSC) which can reliably predict progression to endstage liver disease or cholangiocarcinoma (CCA) development. This and previous studies2,,3,4 ignite new sparks toward exploration of derangement of the gut-liver axis in PSC and holds promise for the discovery of effective medical therapy that are currently lacking.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk primary sclerosing cholangitis hepatology autoimmune liver disease liver transplantation biliary tract liver fibrosis cholangiocarcinoma inflammation
Megjelenés:	Alimentary Pharmacology and Therapeutics. - 53 : 2 (2021), p. 350-351. -
További szerzők:	Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00048 GINOP BO/00232/17/5 Egyéb
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: